iPCS cell modeling of inherited cardiac arrhythmias

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 9, 2014, Pages

  Shinnawi, Rami ^a   Gepstein, Lior ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Cardiology Department   (Israel)

Author keywords

Arrhythmogenic right ventricular cardiomyopathy; Cardiomyocytes; Catecholaminergic polymorphic ventricular tachycardia; Disease modeling; Induced pluripotent stem cells; Inherited cardiac arrhythmias; Long QT syndrome

Indexed keywords

CALCIUM;

ARTICLE; BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; GENETIC DISORDER; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; LONG QT SYNDROME 3; LONG QT SYNDROME 8; NONHUMAN; PLURIPOTENT STEM CELL;

EID: 84905317561     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0331-4     Document Type: Article

References (56)

1. Remme CA. Transgenic models of cardiac arrhythmias and sudden death. Front Physiol. 2013;4:60. doi:10.3389/fphys.2013.00060.
2. Remme CA, Wilde AA, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med. 2008;18(3):78-87. doi:10.1016/j.tcm.2008.01.002. (Pubitemid 351626603)
3. Moretti A, Laugwitz KL, Dorn T, Sinnecker D, Mummery C. Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med. 2013;3(11). doi:10.1101/cshperspect.a014027
4. Hoekstra M, Mummery CL, Wilde AA, Bezzina CR, Verkerk AO. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol. 2012;3:346. doi:10.3389/fphys.2012.00346.
5. .•• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72. Revolutionary study describing that mature somatic cells can be reprogrammed into pluripotent stem cells by introducing a set of transcription factors. (Pubitemid 350138099)
6. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. (Pubitemid 44233629)
7. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104(4):e30-41.
8. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation. 2009;120(15):1513-23.
9. .•• Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363(15):1397-409. The first study demonstrating that hiPSC-derived cardiomyocytes from a patient carrying inherited cardiac arrythmia can recapitulate the patient's disease phenotype.
10. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, et al.Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res. 2012;95(4):419-29. doi:10.1093/cvr/cvs206.
11. .•• Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225-9. Pioneering study demonstrating that hiPSC-CMs derived from healthy and diseased patients could serve for drug testing ameliorating or aggravating disease phenotype, both at the single and multicellular level.
12. .• Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013. doi:10.1038/emboj.2013.240. Description of the use of an isogenic control line, by correcting the causative mutation, as an optimal control since it eliminates patient-specific genetic background differences between the control and the diseased cells.
13. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32(8):952-62. doi:10.1093/eurheartj/ehr073.
14. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012;5(2):220-30. doi:10.1242/dmm.008409.
15. Terrenoire C, Wang K, Tung KW, Chung WK, Pass RH, Lu JT, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol. 2013;141(1):61-72. doi:10.1085/jgp. 201210899.
16. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NB, et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol. 2013;168(6):5277-86. doi:10.1016/j.ijcard.2013.08. 015.
17. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471(7337):230-4. doi:10.1038/nature09855.
18. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation. 2012;125(25):3079-91. doi:10.1161/CIRCULATIONAHA. 111.066092.
19. Jung CB, Moretti A. Mederos y Schnitzler M, Iop L, Storch U, Bellin M et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO. Mol Med. 2012;4(3):180-91.
20. Fatima A, Xu G, Shao K, Papadopoulos S, Lehmann M, Arnaiz-Cot JJ, et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem. 2011;28(4):579-92. doi:10.1159/000335753.
21. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol. 2012;60(11):990-1000. doi:10.1016/j.jacc.2012.02.066.
22. Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, et al. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One. 2012;7(9):e44660. doi:10.1371/journal.pone.0044660.
23. Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M, et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2013;4:e843. doi:10.1038/cddis.2013.369.
24. Novak A, Barad L, Zeevi-Levin N, Shick R, Shtrichman R, Lorber A, et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J Cell Mol Med. 2012;16(3):468-82. doi:10.1111/j.1582-4934.2011.01476.x.
25. Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557-68. doi:10.1161/CIRCGENETICS.113.000188.
26. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494(7435):105-10. doi:10.1038/nature11799.
27. Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013;34:1122-33.
28. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol. 2008;51(24):2291-300. doi:10.1016/j.jacc.2008.02.068. (Pubitemid 351783362)
29. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2(5):507-17. doi:10.1016/j.hrthm. 2005.01.020. (Pubitemid 40521365)
30. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat. 2009;30(11):1486-511. doi:10.1002/humu.21106.
31. Li G, Cheng G, Wu J, Ma S, Sun C. New iPSC for old long QT syndrome modeling: Putting the evidence into perspective. Exp Biol Med (Maywood). 2014;239(2):131-40. doi:10.1177/1535370213514000.
32. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol. 1999;34(3):823-9. (Pubitemid 29436190)
33. Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, et al. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A. 2012;109(29):11866-71. doi:10.1073/pnas.1205266109.
34. Malan D, Friedrichs S, Fleischmann BK, Sasse P. Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ Res. 2011;109(8):841-7. doi:10.1161/CIRCRESAHA.111.243139.
35. Chandra R, Starmer CF, Grant AO. Multiple effects of KPQ deletion mutation on gating of human cardiac Na + channels expressed in mammalian cells. Am J Physiol. 1998;274(5 Pt 2):H1643-54.
36. Caspi O, Itzhaki I, Kehat I, Gepstein A, Arbel G, Huber I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 2009;18(1):161-72. doi:10.1089/scd.2007.0280.
37. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127(16):1677-91. doi:10.1161/CIRCULATIONAHA.113.001883.
38. Gyorke S. Molecular basis of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2009;6(1):123-9. doi:10.1016/j.hrthm.2008.09.013.
39. Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol. 2009;34(1):9-43. doi:10.1016/j.cpcardiol.2008.09.002.
40. Eldar M, Pras E, Lahat H. Amissensemutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Cold Spring Harb Symp Quant Biol. 2002;67:333-7. (Pubitemid 36775528)
41. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69(6):1378-84. doi:10.1086/324565. (Pubitemid 33124218)
42. Zhang XH, Haviland S, Wei H, Saric T, Fatima A, Hescheler J, et al. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPSCM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium. 2013;54(2):57-70. doi:10.1016/j.ceca. 2013.04.004.
43. Thiene G, Corrado D, Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J Rare Dis. 2007;2:45. doi:10.1186/1750-1172- 2-45.
44. Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol. 2012;9(4):223-33. doi:10.1038/nrcardio.2011. 173.
45. Cerrone M, Noorman M, Lin X, Chkourko H, Liang FX, van der Nagel R, et al. Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. Cardiovasc Res. 2012;95(4):460-8. doi:10.1093/cvr/cvs218.
46. Gherghiceanu M, Barad L, Novak A, Reiter I, Itskovitz-Eldor J, Binah O, et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J Cell Mol Med. 2011;15(11):2539-51. doi:10.1111/j.1582-4934.2011.01417.x.
47. Lundy SD, Zhu WZ, Regnier M, Laflamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22(14):1991-2002. doi:10.1089/scd.2012.0490.
48. Lieu DK, Fu JD, Chiamvimonvat N, Tung KC, McNerney GP, Huser T, et al. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol. 2013;6(1):191-201. doi:10.1161/CIRCEP.111.973420.
49. Bett GC, Kaplan AD, Lis A, Cimato TR, Tzanakakis ES, Zhou Q et al. Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells. Heart Rhythm. 2013. doi:S1547-5271(13)01071-0.
50. Halbach M, Peinkofer G, Baumgartner S, Maass M, Wiedey M, Neef K et al. Electrophysiological integration and action potential properties of transplanted cardiomyocytes derived from induced pluripotent stem cells. Cardiovasc Res. 2013. doi:cvt213.
51. Martins-Taylor K, Xu RH. Concise review: Genomic stability of human induced pluripotent stem cells. Stem Cells. 2012;30(1):22-7. doi:10.1002/stem.705.
52. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29(8):731-4. doi:10.1038/nbt.1927.
53. Sakuma T, Hosoi S, Woltjen K, Suzuki K, Kashiwagi K, Wada H, et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells. 2013;18(4):315-26. doi:10.1111/gtc.12037.
54. Maass K, Lu J, See F, D'Souza S, Fishman GI. Development of a Mouse ESC Reporter Line to Isolate Purkinje-Like Cardiac Conduction System Cells. Heart Rhythm. 2013;10(11):1748. doi:10.1016/j.hrthm.2013.09.036.
55. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848-57. doi:10.1073/pnas.1200250109.
56. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc. 2013;8(1):162-75. doi:10.1038/nprot.2012.150.